Goldman Sachs’s Applied Therapeutics APLT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-146,219
Closed -$14.6K 6455
2025
Q4
$14.6K Sell
146,219
-8,922
-6% -$5.67K ﹤0.01% 6357
2025
Q3
$93.8K Sell
155,141
-575,577
-79% -$271K ﹤0.01% 6091
2025
Q2
$227K Buy
730,718
+414,488
+131% +$160K ﹤0.01% 5598
2025
Q1
$155K Sell
316,230
-705,377
-69% -$415K ﹤0.01% 5692
2024
Q4
$875K Buy
1,021,607
+203,841
+25% +$1.28M ﹤0.01% 4907
2024
Q3
$6.95M Buy
817,766
+665,317
+436% +$3.92M ﹤0.01% 3058
2024
Q2
$712K Sell
152,449
-562,759
-79% -$2.66M ﹤0.01% 4628
2024
Q1
$4.86M Buy
715,208
+698,456
+4,169% +$3.14M ﹤0.01% 3115
2023
Q4
$56.1K Buy
+16,752
New +$41.7K ﹤0.01% 5360
2022
Q4
Sell
-28,321
Closed -$26K 5964
2022
Q3
$26K Buy
28,321
+12,187
+76% +$14.6K ﹤0.01% 5887
2022
Q2
$15K Sell
16,134
-78,530
-83% -$129K ﹤0.01% 6215
2022
Q1
$200K Buy
94,664
+19,159
+25% +$51.3K ﹤0.01% 5884
2021
Q4
$676K Buy
75,505
+13,415
+22% +$176K ﹤0.01% 5152
2021
Q3
$1.03M Buy
62,090
+2,545
+4% +$43.9K ﹤0.01% 4713
2021
Q2
$1.24M Sell
59,545
-11,113
-16% -$210K ﹤0.01% 4606
2021
Q1
$1.32M Buy
70,658
+12,499
+21% +$270K ﹤0.01% 4390
2020
Q4
$1.28M Buy
58,159
+45,711
+367% +$952K ﹤0.01% 4039
2020
Q3
$258K Buy
12,448
+252
+2% +$6.55K ﹤0.01% 4807
2020
Q2
$441K Buy
12,196
+1,441
+13% +$60.3K ﹤0.01% 4444
2020
Q1
$352K Buy
+10,755
New +$435K ﹤0.01% 4408
2019
Q3
Sell
-24,654
Closed -$203K 5151
2019
Q2
$203K Buy
+24,654
New +$233K ﹤0.01% 4784

Goldman Sachs's APLT Position: Q1 2026 in Review

Goldman Sachs sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 146,219 shares — an estimated $14.6K sold.

Goldman Sachs first reported a position in APLT in Q2 2019 and held it in 21 quarters. The position peaked at $6.95M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.

  • Goldman Sachs reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 146,219 Applied Therapeutics shares in Q1 2026, an estimated $14.6K.
  • Goldman Sachs first reported a position in Applied Therapeutics in Q2 2019 and held it in 21 quarters.
  • Goldman Sachs's Applied Therapeutics position peaked at $6.95M in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.